MiniMed, formerly known as Medtronic Diabetes, showcased feasibility study results for its next-generation algorithm, Vivera at this years Advanced Technologies & Treatment for Diabetes (ATTD) in Barcelona. The new algorithm is a fully closed-loop insulin delivery system that represents a significant step beyond today's MiniMed 780G algorithm. Current FDA-cleared systems are considered "hybrid closed-loop," meaning users still need to bolus for meals to achieve optimal glucose control. Vivera could change that, by delivering optimal results while giving users the freedom to announce meals on their own terms. We're working on a Vivera feasibility trial deep-dive for All Access members, but for now, here's what you should know about the upcoming algorithm.

Vivera is built entirely from the ground up, not an incremental update but a completely new algorithm. It's designed to improve the experience for both pump users and their healthcare providers. For patients, meal announcements become fully optional, and MiniMed is eliminating SmartGuard exits, meaning fewer interruptions and less day-to-day user intervention. The algorithm will introduce an expanded range of glucose targets, starting as low as 90 mg/dL, and then options at 100, 110, and 120, plus two new higher targets at 130 and 140. MiniMed says its redesigned temp target sits at 150 mg/dl.

Getting started on MiniMed pumps will be easier thanks to the 48 hours SmartGuard warmup period going away and the algorithm automatically adjusting. These new enhancements could also make prescribing the supported pumps easier on healthcare providers.

Joining today’s unannounced Meal Detection is machine learning to each individuals physiology. The algorithm learns from patterns of its user. If a user has hypos at night, it adapts to those trends to prevent hypos in the evening.

So, when will users get their hands on this algorithm? Well, it’s still a bit early. The feasibility study included 14 adults and 13 children and lasted over the span of three months. Overall, the trail showed promising results which I’ll get cover more in-depth in my feasibility trial deep dive article. For now, one example really stuck out—MiniMed shared that one participant, aged 13, saw a decrease in A1C from 8% to 6.7% after three months using Vivera. Exciting stuff, but just one example, and many more to uncover.

Next up is a pivotal trial, which could take about six months. There’s no word yet on when it will begin or how long clearance might take after that, but it’s exciting to see companies working toward systems that require less decision-making for people who want more freedom and less work.

Vivera is not the only exciting development worth paying attention to. Insulet dropped promising results for its own fully-closed loop algorithm for type 2 diabetes at ATTD. Plus, MiniMed has more in the pipeline with two next-generation insulin pumps in the works, and has already submitted the MiniMed Flex to the FDA for clearance. ATTD 2026 has been full of big news, and we are covering it all. Check out our other stories to keep up with everything coming out of the conference.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.